The Medicines Co. Sets The (Commercial) Stage For New Launches
This article was originally published in The Pink Sheet Daily
CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.
You may also be interested in...
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.